• Publications
  • Influence
Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids
Plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides are among the most important risk factors for coronary arteryExpand
  • 2,968
  • 156
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis ofExpand
  • 2,371
  • 83
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.
Atherosclerotic cardiovascular disease results in >19 million deaths annually, and coronary heart disease accounts for the majority of this toll. Despite major advances in treatment of coronary heartExpand
  • 2,639
  • 47
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
BACKGROUND In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDLExpand
  • 1,468
  • 46
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
CONTEXT Prior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression usingExpand
  • 1,712
  • 45
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.
BACKGROUND Recruitment of circulating leukocytes at sites of atherosclerosis is mediated through a family of adhesion molecules. The function of circulating forms of these adhesion molecules remainsExpand
  • 1,294
  • 34
Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association
There is increasing interest in utilizing novel markers of cardiovascular disease risk, and consequently, there is a need to assess the value of their use. This scientific statement reviews currentExpand
  • 994
  • 32
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
BACKGROUND Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-termExpand
  • 696
  • 32
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study.
OBJECTIVES We evaluated whether carotid intima-media thickness (CIMT) and the presence or absence of plaque improved coronary heart disease (CHD) risk prediction when added to traditional riskExpand
  • 710
  • 29
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.
OBJECTIVE To assess the magnitude of the association between the National Cholesterol Education Program's Third Adult Treatment Panel Report (ATP III) definition of the metabolic syndrome andExpand
  • 928
  • 28